Drug

Vilzemetkib clinical trials

Also written AL2846.

studies test it: 8
open now: 1
in phase 3: 1
first study started: 2016

How each study uses vilzemetkib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the vilzemetkib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

AL2846 capsule: 3
AL2846 capsules: 3

Development codes

AL2846: 2

Studies by the year they started

8 studies that test it; most in 2023 (2)

Studies that test vilzemetkib, by start year
Year	Studies
2016	1
2018	1
2020	1
2021	1
2022	1
2023	2
2025	1

By phase

A phase 1/2 study counts in both.

Phase 1: 5
Phase 2: 5
Phase 3: 1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Ovarian Neoplasms: 1
Pancreatic Neoplasms: 1
Thyroid Neoplasms: 1
Neurofibromatoses: 1

Who runs them

Industry 8 · Other 0

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (8)

Often tested with

Tested in the same studies.

Benmelstobart (1)

Related medicines

As reviewed, each with the page that says it.

One of Protein Kinase Inhibitors source
One of Tyrosine kinase inhibitors (TKIs) source

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1, 1 in phase 3

Studies that test vilzemetkib, phase 3 first.

Jan 2027A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid CarcinomaPhase 3 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Studies

Open first, then newest update. How each study uses vilzemetkib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 8

Given beside what is tested · 1 — vilzemetkib is usual care or a partner of the new treatment

A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal CancerStatus unknownPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04337879Written as AL2846

Codes

What other systems call vilzemetkib · ClinicalTrials.gg INT016562

UNII (FDA) FJ4Y6XP24YVILZEMETKIBOne source FDA
NCI Thesaurus C129314VilzemetkibOne source FDA

System	Code	Name there	Checked by
UNII (FDA)	FJ4Y6XP24Y	VILZEMETKIB	One source FDA
NCI Thesaurus	C129314	Vilzemetkib	One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.